Pulmonary arterial hypertension is a progressive pulmonary vascular disease characterized by elevated pulmonary arterial pressure and vascular remodeling, which can lead to right ventricular failure.
Merck reported Phase 2 CADENCE results showing WINREVAIR met the primary endpoint in adults with CpcPH-HFpEF. The company said the data support advancement into a registrational Phase 3 study.
Phase 3 trial results show seralutinib missed its primary endpoint in PAH but showed benefit in advanced disease subgroups. Meanwhile, Winrevair demonstrated significant reductions in pulmonary vascular resistance in heart failure-related pulmonary hypertension in a Phase 2 study.
Merck will acquire Terns Pharmaceuticals for $6.7 billion to bolster its cancer pipeline ahead of Keytruda's 2028 patent expiration. The deal gives Merck access to TERN-701, an oral tyrosine kinase inhibitor for chronic myeloid leukemia. Merck projects over $70 billion in commercial opportunities from its pipeline by the mid-2030s.
Global orphan drug sales are forecast to reach $409 billion by 2032, representing one-fifth of prescription drug sales, with Johnson & Johnson and Argenx leading the market amid regulatory uncertainty.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.
Zydus Lifesciences received USFDA final approval for 32 mg bosentan tablets for pediatric PAH and Ammonium Lactate Cream, 12%, while launching an affordable respiratory device in India.
Gossamer Bio's seralutinib narrowly missed its primary endpoint in the Phase 3 PROSERA study for pulmonary arterial hypertension, achieving a p-value of 0.0320 versus the prespecified threshold of 0.025, though showing stronger results in intermediate- and high-risk patients.
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07600723 |
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07481981 |
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07464184 |
Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension |
NOT_YET_RECRUITING | NA |
| NCT07441200 |
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07391228 |
Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) |
ACTIVE_NOT_RECRUITING | |
| NCT07374302 |
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice |
NOT_YET_RECRUITING | |
| NCT07366879 |
Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension |
RECRUITING | NA |
| NCT07365332 |
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) |
RECRUITING | PHASE3 |
| NCT07312227 |
A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia |
ACTIVE_NOT_RECRUITING | |
| NCT07218029 |
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) |
RECRUITING | PHASE3 |
